FORM 12b-25




SEC File Number: 001-33624

CUSIP Number: 023435209


 (Check one:)

[X] Form 10-K [  ] Form 20-F [  ] Form 11-K [  ] Form 10-Q [  ] Form 10-D [  ] Form N-SAR

[  ] Form N-CSR

  For Period Ended: December 31, 2016
  [  ] Transition Report on Form 10-K
  [  ] Transition Report on Form 20-F
  [  ] Transition Report on Form 11-K
  [  ] Transition Report on Form 10-Q
  [  ] Transition Report on Form N-SAR
  For the Transition Period Ended:                ___


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not applicable




Full Name of Registrant: Amedica Corporation  
Former Name if applicable:    
Address of Principal Executive Office:

1885 W 2100 S

Salt Lake City, UT 84119







PART II - RULE 12B-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed: (Check box if appropriate)


[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 [  ] (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, NCSR, or the transition report or portion thereof, could not be filed within the prescribed period.


Amedica Corporation (the “Company”) has not yet completed certain financial and other information necessary for an accurate and full completion of the Annual Report. As a result, the Company cannot, without unreasonable effort or expense, file its Form 10-K on or prior to the prescribed due date. The Company expects to file its Form 10-K within fifteen (15) calendar days of the prescribed due date.




(1) Name and telephone number of person to contact in regard to this notification:
  David Truetzel, Audit Committee Chairman (314) 448-1316
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding twelve months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s) [X] Yes [  ] No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [  ] Yes [X] No
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and if appropriate, state the reasons why a reasonable estimate of the results cannot be made.




Amedica Corporation has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.


Date: March 31, 2017 By: /s/ B. Sonny Bal
    B. Sonny Bal, MD
    CEO and President